Harvard Bioscience (HBIO) 10-Q 6 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	Jun. 30, 2015
Amendment flag	false
Document Period Focus	Q2
Document Fiscal Year Focus	2,015
Current fiscal year end date	--12-31
Entity central index key	1,123,494
Entity current reporting status	Yes
Entity filer category	Accelerated Filer
Entity registrant name	HARVARD BIOSCIENCE INC
Entity voluntary filers	No
Entity well known seasoned issuer	No
Entity common stock shares outstanding		33,925,864
Trading Symbol	HBIO

Statements of Financial Positio

Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 7,402	$ 14,134
Accounts receivable, net of allowance for doubtful accounts of $320 and $328, respectively	18,542	16,141
Inventories	23,068	20,531
Deferred income tax assets - current	2,608	1,515
Other receivables and other assets	4,922	4,742
Total current assets	56,542	57,063
Property, plant and equipment, net	5,764	5,190
Deferred income tax assets - non-current	11,018	11,056
Amortizable intangible assets, net	22,538	21,153
Goodwill	41,081	39,822
Other indefinite lived intangible assets	1,228	1,252
Other assets	406	380
Total Assets	138,577	135,916
Current liabilities:
Current portion, long-term debt	5,000	5,000
Accounts payable	8,834	6,294
Deferred revenue	864	655
Accrued income taxes payable	159	554
Deferred income tax liabilities - current	246	121
Accrued expenses	4,438	4,452
Other liabilities - current	1,692	1,023
Total current liabilities	21,233	18,099
Long-term debt	15,650	16,450
Deferred income tax liabilities - non-current	2,206	1,325
Other liabilities- non current	4,675	4,574
Total liabilities	43,764	40,448
Stockholders Equity Abstract
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 41,661,261 and 40,308,763 shares issued and 33,915,754 and 32,563,256 shares outstanding, respectively	415	397
Additional paid-in-capital	209,793	206,656
Accumulated deficit	(93,736)	(92,684)
Accumulated other comprehensive loss	(10,991)	(8,233)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	94,813	95,468
Total liabilities and stockholders' equity	$ 138,577	$ 135,916

Statements of Financial Positi3

Statements of Financial Position (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
CONSOLIDATED BALANCE SHEETS
Allowance for doubtful accounts	$ 320	$ 328
Preferred Stock Par value	$ 0.01	$ 0.01
Preferred Stock - Shares Authorized	5,000,000	5,000,000
Common stock par value	$ 0.01	$ 0.01
Common Stock- Shares Authorized	80,000,000	80,000,000
Common Stock- Shares Issued	41,661,261	40,308,763
Common Stock- Shares Outstanding	33,915,754	32,563,256
Treasury Stock common shares	7,745,507	7,745,507

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 28,800	$ 26,958	$ 54,563	$ 52,851
Cost of revenues (exclusive of items shown separately below)	16,205	14,680	30,490	28,812
Gross profit	12,595	12,278	24,073	24,039
Sales and marketing expenses	5,128	4,557	10,327	8,989
General and administrative expenses	4,922	3,997	9,753	8,248
Research and development expenses	1,714	1,284	3,462	2,257
Restructuring charges (credits)	54	115	111	252
Amortization of intangible assets	678	587	1,471	1,221
Total Operating Expenses	12,496	10,540	25,124	20,967
Operating income	99	1,738	(1,051)	3,072
Other (expense) income:
Foreign exchange	(134)	(67)	89	(148)
Interest expense	(215)	(248)	(437)	(513)
Interest income	3	12	4	26
Other income (expense), net	(180)	(165)	(796)	(148)
Other expense, net	(526)	(468)	(1,140)	(783)
Income from continuing operations before income taxes	(427)	1,270	(2,191)	2,289
Total Income Tax Expense	(776)	248	(1,139)	548
Net income (loss)	$ 349	$ 1,022	$ (1,052)	$ 1,741
Earnings (loss) per share:
Basic earnings per common share	$ 0.01	$ 0.03	$ (0.03)	$ 0.05
Diluted Earnings Per Common Share	$ 0.01	$ 0.03	$ (0.03)	$ 0.05
Weighted average common shares:
Basic	33,569,180	32,045,314	33,240,467	31,946,654
Diluted	35,025,650	32,945,932	33,240,467	32,935,455
Consolidated Statements of Comprehensive Income [Abstract]
Foreign currency translation adjustments	$ 1,760	$ 369	$ (2,737)	$ 584
Other Comprehensive Income Derivatives Qualifying As Hedges Net Of Tax Period Increase Decrease [Abstract]
Loss on derivative instruments designated and qualifying as cash flow hedges	(12)	(56)	(71)	(80)
Amounts reclassified from accumulated other comprehensive income to net income	24	34	50	69
Unrealized losses on pension benefit obligation, net of tax	0	(484)	0	(484)
Total Comprehensive Income (Loss), Net of Tax, total	$ 2,121	$ 885	$ (3,810)	$ 1,830

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income (loss)	$ (1,052)	$ 1,741
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense	1,272	919
Depreciation	769	608
(Gain) loss on sales of fixed assets	11	(4)
Non cash restructuring charge	(64)	(118)
Amortization Of Catalog Costs	8	24
Provision for allowance for doubtful accounts	3	(30)
Amortization of intangible assets	1,471	1,221
Amortization of deferred financing costs	30	30
Deferrred Income Taxes	(1,027)	119
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	(2,136)	(294)
Increase in inventories	(1,242)	(1,312)
Increase in other receivables and other assets	(240)	(864)
Increase in trade accounts payable	2,451	349
(Decrease) increase in accrued income taxes	(395)	(7)
Increase in accrued expenses	(660)	51
(Decrease) increase in deferred revenue	216	(36)
Increase (decrease) in other liabilities	(396)	89
Net cash provided by operating activities	(981)	2,486
Cash flows (used in) provided by investing activities:
Additions to property, plant and equipment	(1,640)	(744)
Proceeds from sales of property, plant and equipment	15	78
Acquisitions, net of cash acquired	(4,545)	0
Net cash used in investing activities	(6,170)	(666)
Cash flows provided by (used in) financing activities:
Repayments of debt	(4,850)	(2,500)
Net proceeds from issuance of debt	4,050	0
Payments of debt issuance costs	(32)	0
Net proceeds from issuance of common stock	1,864	1,001
Net cash (used in) provided by financing activities	1,032	(1,499)
Effect of exchange rate changes on cash	(613)	342
Increase in cash and cash equivalents	(6,732)	663
Cash and cash equivalents at the begining of period	14,134	25,771
Cash and cash equivalents at the end of period	7,402	26,434
Supplemental disclosures of cash flow information [Abstract]
Cash paid for interest	427	458
Cash paid for income taxes, net of refunds	$ 312	$ 688

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Text Block]	HARVARD BIOSCIENCE, INC. NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of June 30, 2015 and for the three and six months ended June 30, 2015 and 2014 have been prepared by the Company pursuant to the rules a nd regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been conde nsed or omitted pursuant to such rules and regulations. The December 31, 2014 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annua l Report on Form 10-K for the fiscal year ended December 31, 2014 , which was filed with the SEC on March 12, 2015. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2015 , results of operations and comprehensive (loss) income for the three and six months ended June 30, 2015 and 2014 and cash flows for the six months ended June 30, 2015 and 2014 , as applicable, have been made. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future periods. Summary of Significant Accounting Poli cies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31 , 2014 , which was filed with the SEC on March 12, 2015.

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	6 Months Ended
	Jun. 30, 2015
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2 . Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in U.S. GAAP. Under this standard, revenue will be re cognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. At its July 2015 meeting, the FASB agreed to defer the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar year-end public entities. The Company is assessing the new standard and has not yet determined the impact to the consolida ted financial statements. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . The update requires debt issuance costs related to a recognized debt liabili ty to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability, instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rat e. The update requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previousl y issued. The Company is evaluating the impact of ASU 2015-03 on its consolidated financial statements and the possibility of early adoption by the Company. In July 2015, the FASB issued ASU 2015-11, Simplifying Measurement of Inventory . The update requir es measurement of most inventory “at the lower of cost and net realizable value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured under the last-in, first-out (LIFO) method or the retail inven tory method (RIM). ASU 2015-11 requires prospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company is evaluating the impact of ASU 2015-11 on its consolidated financial statements and the possibility of early adoption by the Company.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2015
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income Disclosure [Text Block]	3 . Accumulated Other Comprehensive Loss Changes in each component of accumulated other comprehensive loss , net of tax are as follows: Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2014 $ (4,658) $ (18) $ (3,557) $ (8,233) Other comprehensive loss before reclassifications (2,737) (71) - (2,808) Amounts reclassified from AOCI - 50 - 50 Other comprehensive loss (2,737) (21) - (2,758) Balance at June 30, 2015 $ (7,395) $ (39) $ (3,557) $ (10,991)

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2015
Acquisition Disclosure [Abstract]
Acquisitions Disclosure [Text Block]	4. Acquisitions The Company completed one acquisition during the six months ended June 30, 2015 . HEKA Elektronik On January 8, 2015, the Company, through its wholly-owned Ealing Scientific Limited and Multi Channel Systems MCS GmbH subsidiaries, acquired all of the issued and outstanding shares of HEKA Elektronik (“HEKA”) for approximately $5.9 million, or $4.5 million, net of cash acquired. Included in the acquisition of HEKA are: HEKA Electronik Dr. Schulze GmbH, based in Lambrecht , Germany (“HEKA Germany”) ; HEKA Electronics Incorporated, based in Chester, Nova Scotia, Canada (“HEKA Canada”) ; and HEKA Instruments Incorporated, based in Bellmore, New York. The Company funded the acquisition from its existing cash balances. HEKA is a developer, ma nufacturer and marketer of sophisticated electrophysiology instrumentation and software for biomedical and industrial research applications. This acquisition is complementary to the electrophysiology line currently offered by the Company’s wholly-owned War ner Instruments and MCS subsidiaries. The aggregate purchase price for this acquisition was preliminarily allocated to tangible and intangible assets acquired as follows: (in thousands) Tangible assets $ 4,165 Liabilities assumed (2,819) Net assets 1,346 Goodwill and intangible assets: Goodwill 2,061 Trade name 774 Customer relationships 1,627 Developed technology 1,338 Non-compete agreements 27 Deferred tax liabilities (1,245) Total goodwill and intangible assets, net of tax 4,582 Acquisition purchase price $ 5,928 The estimated purchase price allocation is preliminary and subject to revision. A valuation of the assets acquired and liabilities assumed is being conducted and the final allocation will be made when completed. Goodwill recorded as a result of the acquisition of HEKA is not deductible for tax purposes. The results of operations for HEKA have been included in the Company’s consolidated financial statements from the date of acquisition and are not material. The following consolidated pro forma info rmation is based on the assumption that the acquisition of HEKA occurred on January 1, 2014. Accordingly, the historical results have been adjusted to reflect amortization expense that would have been recognized on such a pro forma basis. The pro forma information is presented for comparative purposes only and is not necessarily indicative of the financial position or results of operations which would have been reported had we completed the acquisition during these periods or which might be report ed in the future. Three Months Ended Six Months Ended June 30, 2014 June 30, 2014 (in thousands) Pro Forma Revenues $ 28,339 $ 55,612 Net income 1,096 1,889 The Company completed two acquisitions during 2014. Multi Channel Systems MCS GmbH On October 1, 2014, the Company, through its wholly-owned Biochrom Limited subsidiary, acquired all of the issued and outstanding shares of Multi Channel Systems MCS GmbH (“MCS”), which has its principal offices in Germany, for approximately $11.2 million, including a working capital adjustment. The Company funded the acquisition from its existing cash balances. MCS is a developer, manufacturer and marke ter of in vitro and in vivo electrophysiology instrumentation for extracellular recording and stimulation. This acquisition is complementary to the in vitro electrophysiology line currently offered by the Company’s wholly-owned Warner Instruments subsidiar y. The aggregate purchase price for this acquisition was preliminarily allocated to tangible and intangible assets acquired as follows: (in thousands) Tangible assets $ 5,442 Liabilities assumed (1,207) Net assets 4,235 Goodwill and intangible assets: Goodwill 3,745 Trade name 1,008 Customer relationships 1,204 Developed technology 2,452 Non-compete agreements 148 Deferred tax liabilities (1,603) Total goodwill and intangible assets, net of tax 6,954 Acquisition purchase price $ 11,189 Goodwill recorded as a result of the acquisition of MCS is not deductible for tax purposes. The results of operations for MCS have been included in the Company’s consolidated financial statements from the date of acquisition and are not material. The following consolidated pro forma information is based on the assumption that the acquisition of MCS occurred on January 1, 2014. Accordingly, the historical results have been adjusted to reflect amortization expense that would have been recognized on such a pro forma basis. The pro forma information is presented for comparative purposes only and is not necessarily indicative of the financial position or results of operations which would have been reported had we completed the acquisition during th ese periods or which might be reported in the future. Three Months Ended Six Months Ended June 30, 2014 June 30, 2014 (in thousands) Pro Forma Revenues $ 28,780 $ 56,492 Net income 1,105 1,906 Triangle BioSystems , Inc. On October 1, 2014, the Company acquired all of the issued and outstanding shares of Triangle BioSystems , Inc. (“TBSI”), which has it s principal offices in North Carolina, for approximately $2.2 million, including a working capital adjustment. The Company funded the acquisition from borrowings under its credit facility. TBSI is a developer, manufacturer and marketer of wireless neural interface equipment to aid in vivo neuroscience research, especially in the fields of electrophysiology, psychology, neurology and pharmacology. This acquisition is complementary to the behavioral neuroscience lines currently offered by the Company’s whol ly-owned Panlab and Coulbourn subsidiaries. The aggregate purchase price for this acquisition was preliminarily allocated to tangible and intangible assets acquired as follows: (in thousands) Tangible assets $ 1,278 Liabilities assumed (530) Net assets 748 Goodwill and intangible assets: Goodwill 946 Trade name 143 Customer relationships 308 Developed technology 363 Non-compete agreements 30 Deferred tax liabilities (325) Total goodwill and intangible assets, net of tax 1,465 Acquisition purchase price $ 2,213 The results of operations for TBSI have been included in the Company’s consolidated financial statements from the date of acquisition and are not material. The Company considers this acquisition immaterial for the purposes of proforma financial statement disclosures. Goodwill recorded as a result of the acquisition of TBSI is not deductible for tax purposes. Direct acquisition costs recorded in other expense, net in the Company’s consolidated statements of operations were $0.2 million and $0.8 million for the three and six months ended June 30, 2015 , respectively, and $0.2 million for both the three and six months ended June 30, 2014 , respectively.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2015
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill And Other Intangible Assets Disclosure [Text Block]	4. Goodwill and Other Intangible Assets Intangible assets consist of the following: Weighted Average June 30, 2015 December 31, 2014 Life (a) (in thousands) Amortizable intangible assets: Gross Accumulated Amortization Gross Accumulated Amortization Existing technology $ 16,399 $ (11,508) $ 15,538 $ (11,198) 7.6 Years Trade names 7,698 (2,826) 7,114 (2,557) 9.5 Years Distribution agreements/customer relationships 23,830 (11,238) 22,730 (10,681) 10.4 Years Patents 259 (76) 256 (49) 3.7 Years Total amortizable intangible assets 48,186 $ (25,648) 45,638 $ (24,485) Indefinite-lived intangible assets: Goodwill 41,081 39,822 Other indefinite-lived intangible assets 1,228 1,252 Total goodwill and other indefinite-lived intangible assets 42,309 41,074 Total intangible assets $ 90,495 $ 86,712 (a) Weighted average life as of June 30, 2015. The change in the carrying amount of goodwill for the six months ended June 30, 2015 is as follows: (in thousands) Balance at December 31, 2014 $ 39,822 Goodwill arising from business combinations 2,061 Effect of change in currency translation (802) Balance at June 30, 2015 $ 41,081 Intangible asset amortization expense was $ 0.7 million and $ 0.6 million for the three months ended June 30, 2015 and 2014 , respectively. Intangible asset amortization expense was $ 1.5 million and $ 1.2 million for the six months ended June 30, 2015 and 2014 , respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be $ 2.8 million for the year ending December 31, 2015 , $ 2.8 million for the year ending December 31, 2016 , $ 2.5 million for the year ending December 31, 2017 , $ 2.4 million for the year ending December 31, 2018 and $ 2.2 million for the year ending December 31, 2019 .

Inventories

Inventories	6 Months Ended
	Jun. 30, 2015
Inventories Disclosure [Abstract]
Inventories Disclosure [Text Block]	5. Inventories Inventories consist of the following: June 30, December 31, 2015 2014 (in thousands) Finished goods $ 10,607 $ 10,138 Work in process 1,256 946 Raw materials 11,205 9,447 Total $ 23,068 $ 20,531

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment Disclosure [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6 . Property , Plant and Equipment Property, plant and equipment consist of the following: June 30, December 31, 2015 2014 (in thousands) Land, buildings and leasehold improvements $ 2,619 $ 2,595 Machinery and equipment 10,172 10,102 Computer equipment and software 7,300 6,322 Furniture and fixtures 1,324 1,125 Automobiles 54 56 21,469 20,200 Less: accumulated depreciation (15,705) (15,010) Property, plant and equipment, net $ 5,764 $ 5,190

Restructuring and Other Exit Co

Restructuring and Other Exit Costs	6 Months Ended
	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring And Other Exit Costs Disclosure [Text Block]	8 . Restructuring and Other Exit Costs Q2 201 5 Restructuring Plan During the second quarter of 201 5 , management of Harvard Bioscience initiated a plan to consolidate the manufacturing operations of HEKA Canad a to HEKA Germa n y in order to create organizational efficiencies . For the three and six months ended June 30, 2015 , t he Company recorded restructuring charges of approximately $ 13,000 representing severance costs . Additional charges related to this plan are expected to be incur re d through the third quarter of 2015 , and include, but are not limited to, contract termination costs, as well as site moving and employee relocation costs. Payments related to this plan are expected to be made through the end of 2015 . Activ ity and liability balances related to these charges were as follows: Severance Costs (in thousands) Restructuring charges $ 13 Cash payments - Restructuring balance at June 30, 2015 $ 13 Q1 201 5 Restructuring Plan During the first quarter of 201 5 , management of Harvard Bioscience initiated a plan to relocate certain manufacturing operations in order to create organizational efficiencies and reduce op erating expenses. The 2015 restructuring plan included plans to consolidate the manufacturing operations of its Coulbourn subsidiary to its headquarters in Holliston, MA. During the six months ended June 30, 2015 , t he Company recorded restructuring charges of app roximate ly $ 0.1 million representing severance costs . Additional charges related to this plan are expected to be incur red through the third quarter of 2015 , and include, but are not limited to, contract termination costs, as well as s ite moving and employee relocation costs. Payments related to this plan are expected to be made through the end of 2015 . Activity and liability balances related to these charges were as follows: Severance Costs (in thousands) Restructuring charges $ 88 Non-cash reversal of restructuring charges (6) Cash payments - Restructuring balance at June 30, 2015 $ 82 201 4 Restructuring Plan During the fourth quarter of 201 4 , management of Harvard Bioscience initiated a plan to relocate certain distribution and manufacturing operations in order to create organizational efficiencies and reduce op erating expenses. The 2014 restructuring plan included plans to relocate the distribution operations of the Company’s Denville subsidiary from New Jersey to North Carolina, as well as consolidating the manufacturing operations of its Biochrom subsidiary to its headquarters in H olliston, MA. During the six months ended June 30, 2015 , t he Company recorded restructuring charges of approximately $ 16,000 . Additional charges related to this plan are expected to be incur red through the third quarter of 2015 , and include, but are not limited to, contract termination costs, as well as site moving and employee relocation costs. Payments related to this plan are expected to be made through the end of 2015 . Activity and liability balances related to these char ges were as follows: Severance Costs Other Total (in thousands) Restructuring balance at December 31, 2014 $ 626 $ - $ 626 Restructuring charges 39 35 74 Non-cash reversal of restructuring charges (58) - (58) Cash payments (129) (35) (164) Effect of change in currency translation 3 - 3 Restructuring balance at June 30, 2015 $ 481 $ - $ 481 2013 Restructuring Plan During the fourth quarter of 2013, the management of Harvard Bioscience initiated a plan to realign global operations to improve organizational efficiencies and reduce operating exp enses throughout the Company. The plan included an approximately 13% reduction in the workforce, as well as the elimination of the position of Chief Operating Officer. No further charges are expected to be incurred on this matter. At December 31, 2014 and June 30, 2015 , the Company had no remaining liability related to this plan on its balance sheet. Activity and liability balances related to these charges in 2014 were as follows: Severance and Related Costs Other Total (in thousands) Restructuring balance at December 31, 2013 $ 1,434 $ - $ 1,434 Restructuring charges 195 175 370 Non-cash reversal of restructuring charges (115) - (115) Cash payments (1,184) (159) (1,343) Restructuring balance at June 30, 2014 $ 330 $ 16 $ 346 2012 Restructuring Plan During 2012, the management of Harvard Bioscience initiated a plan to reduce operating expenses at one of its foreign subsidiaries. No further charges are expected to be incurred on this matter. At December 31, 2014 and June 30, 2015 , the Company had no remaining liability related to this plan on its balance sheet. Activity and liability balances related to these charges in 2014 were as follows: Severance and Related Costs (in thousands) Restructuring balance at December 31, 2013 $ 3 Non-cash reversal of restructuring charges (3) Restructuring balance at June 30, 2014 $ - Aggregate net restructuring charges for the three and six months ended June 30, 2015 and 2014 were as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 (in thousands) Restructuring charges $ 54 $ 115 $ 111 $ 252

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9 . Related Party Transactions On November 1, 2013, the spin-off of Harvard Apparatus Regenerative Technology, Inc. (“HART”) from the Company was completed. In connection with the HART spin-off, the Company entered into various commercial agreements with HART. These agreements include d : ( i ) a Separation and Distribution Agreement; (ii) an Intellectual Property Matters Agreement; (iii) a Product Distribution Agreement; (iv) a Tax Sharing Agreement ; (v) a Transition Services Agreement ; and (vi) a Sublease . The Company recorded revenues of approximately $ 101,000 and $ 149,000 for the three and six months ended June 30, 2015 , respectively, and $ 31,000 and $ 109,000 for the three and six months ended June 30, 2014 , re spectively , as a result of the exclusive distributio n rights pursuant to the Product Distribution Agreement. Th e Company’s operating expenses were reduced by $41,000 and $ 101,000 for the three and six months ended June 30, 2014 , respectively, as a result of the fees the Company charged to HART for services provided pursuant to the Transition Services Agreement. In addition, the Company’s rent expense was reduced by $ 44,000 and $ 86,000 for the three and six months ended June 30, 2015 , respectively, and $ 41,000 and $ 81,000 for the three and six months ended June 30, 2014 , respectively, as a result of sublease rent charged to HART pursuant to the Sublease . David Green, who is currently a Director of the Comp any and was also formerly the Company’s President and interim CEO, was the Chairman and CEO of HART until his resignation on April 17, 2015. Mr. Green remains a member of HART’s Board of Directors. Following Mr. Green’s resignation from HART, the Company has determined that it is no longer a related party with HART. As part of the acquisitions of MCS and TBSI, the Company signed lease agreements with the former owners of the acquired companies. The principals of such former owners were employees of the Com pany as of June 30, 2015 . Pursuant to the lease agreement , the Company incurred rent expense of approximately $ 58,000 and $ 113,000 to the former owners of MCS for the three and six months ended June 30, 2015 , respectively . Pursuant to the lease agreement , the Company incurred rent expense of approximately $ 11,000 and $ 21,000 to the former owner of TBSI for the three and six months ended June 30, 2015 , respectively .

Warranties

Warranties	6 Months Ended
	Jun. 30, 2015
Warranties Disclosure [Abstract]
Warranties Disclosure [Text Block]	10 . Warranties Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows: Beginning Additions/ Ending Balance Payments (Credits) Other Balance (in thousands) Year ended December 31, 2014 $ 305 (102) 49 - $ 252 Six months ended June 30, 2015 $ 252 (25) (73) 3 $ 157

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2015
Employee Benefit Plans Disclosure [Abstract]
Employee Benefit Plans Disclosure [Text Block]	11 . Employee Benefit Plans Certain of the Company’s subs idiaries in the United Kingdom, or UK, Harvard Apparatus Limited and Biochrom Limited, maintain contributory, defined benefit or defined contribution pension plans for substantially all of their employees. As of the quarter ended September 30, 2014 , the principal employer of the Harvard Apparatus Limited pension plan was changed from Harvard Apparatus Limited to Biochrom Limited. As of the quarter ended June 30, 2014 , these defined benefit pension plans were closed to new employees, as well as closed to the future accrual of benefits for existing employees. The components of the Company’s defined benefit pension expense were as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 (in thousands) Components of net periodic benefit cost: Service cost $ - $ (8) $ - $ - Interest cost 190 227 367 448 Expected return on plan assets (179) (167) (345) (330) Net amortization loss 81 46 156 91 Net periodic benefit cost $ 92 $ 98 $ 178 $ 209 For the three months ended June 30, 2015 and 2014 , the Company contributed $ 0.2 million , for both periods , to its defined benefit pension plans. For the six months ended June 30, 2015 and 2014 , the Company contributed $ 0.4 million , for both periods , to its defined benefit pension plans. The Company expects to contribute approximately $0.4 million to its defined benefit pension plans during the remainder of 2015 . During the three months ende d June 30, 2014 the Company wrote down its Level 3 investment in a longevity fund by an additional $0.6 million, which reduced its value to $0. The impact on accumulated other comprehensive loss was $0.5 million, net of tax. The longevity fund invests in a portfolio of physical life insurance settlements that had been historically valued using the net asset values provided by the fund. Since June 2011, the fund has been closed to all activity. The write down during the three months ended June 30, 2014 was due, in part, to communication from the longevity fund regarding its continued illiquidity and inactivity. There has been no change in the status of the longevity fund since the quarter ended June 30, 2014. As of June 30, 2015 and December 31, 2014 , the Company had an underfunded pension liability of approximately $4.6 million and $4.4 million, respectively, included in the other liabilities – non-current line item in the consolidated balance sheets .

Leases

Leases	6 Months Ended
	Jun. 30, 2015
Leases Disclosure [Abstract]
Leases Disclosure [Text Block]	12 . Leases The Company has noncancelable operating leases for office and warehouse space expiring at various dates through 2020 and thereafter. Rent expense, which is recorded on a straight-line basis, is estimated to be $ 2.2 million for the year ended December 31, 2015 . Rent expense was approximately $ 0.6 million and $ 1.2 million for the three and six months ended June 30, 2015 , respectively. Rent expense was approximately $ 0.4 million and $ 0.8 million for the three and six months ended June 30, 2014 , respectively. Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at June 30, 2015 , are as follows: Operating Leases (in thousands) 2016 $ 1,631 2017 1,539 2018 1,511 2019 1,315 2020 1,315 Thereafter 4,502 Net minimum lease payments $ 11,813

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2015
Capital Stock Disclosure [Abstract]
Capital Stock Disclosure [Text Block]	13 . Capital Stock Common Stock On February 5, 2008, the Company’s Board of Directors adopted a Shareholder Rights Plan and declared a dividend distribution of one preferred stock purchase right for each outstanding share of the Company’s common stock to shareholders of record as of the close of business on February 6, 2 008. Initially, these rights will not be exercisable and will trade with the shares of the Company’s common stock. Under the Shareholder Rights Plan, the rights generally will become exercisable if a person becomes an “acquiring person” by acquiring 20% or more of the common stock of the Company or if a person commences a tender offer that could result in that person owning 20% or more of the common stock of the Company. If a person becomes an acquiring person, each holder of a right (other than the acquiri ng person) would be entitled to purchase, at the then-current exercise price, such number of shares of preferred stock which are equivalent to shares of the Company’s common stock having a value of twice the exercise price of the right. If the Company is a cquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company’s common stock having a value of twice the ex ercise price of the right. Preferred Stock The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may exercise th is authority without any further approval of stockholders. As of June 30, 2015 , the Company had no preferred stock issued or outstanding . Employee Stock Purchase Plan (as amended, the “ESPP”) In 2000, the Company approved the ESPP . Under thi s ESPP , participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company’s common stock. At the conclusion of the period, participating employee s can purchase shares of the Company’s common stock at 85% of the lower of the fair market value of the Company’s common stock at the beginning or end of the period. Shares are iss ued under the ESPP for the six-month periods ending June 30 and December 31. Under this plan, 750,000 shares of common stock are authorized for issuance of which 611,369 shares were issue d as of June 30, 2015 . During the three months ended June 30, 2015 and 2014 , the Company issued 26,181 shares and 31,116 shares, respectively, of the Company’s common stock under the ESPP. Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the “Third A&R Plan”) The Second Amendment to the Third A&R Plan ( the “Amendment ”) was adopted by the Board of Directors on April 3, 2015. Such A mendment was approved by the stockholders at the Company’s 2015 Annual Meeting. The Amendment made the following change to the Third A&R Plan : The aggregate number of shares authorized for issuance under the Third A&R Plan was increased by 2,500,000 shares to 17,508,929. Stock-Based Payment Awards The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricte d stock units and employee stock purchases related to the ESPP. Stock option and restricted stock unit activity under the Company’s Third A&R Plan for the six months ended June 30, 2015 was as follows: Stock Options Restricted Stock Units Weighted Stock Average Restricted Options Exercise Stock Units Grant Date Outstanding Price Outstanding Fair Value Balance at December 31, 2014 6,263,112 $ 3.42 306,397 $ 4.30 Granted 863,000 5.51 254,685 5.56 Exercised (1,710,681) 3.04 - - Vested (RSUs) - - (237,188) - Cancelled / forfeited (246,055) 4.01 - - Balance at June 30, 2015 5,169,376 $ 3.87 323,894 $ 5.30 The weighted average fair value of the options granted under the Third A&R Plan during the three months ended June 30, 2015 and 2014 was $ 2.08 and $ 2.20 , respectively. The weighted average fair value of the options granted under the Third A&R Plan during the six months ended June 30, 2015 and 2014 was $ 2.21 and $ 2.19 , respectively . The following assumptions were used to estimate the fair value of stock options gran ted during the three and six months ended June 30, 2015 and 2014 : Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Volatility 39.35 % 57.16 % 41.08 % 56.83 % Risk-free interest rate 1.70 % 1.80 % 1.72 % 1.78 % Expected holding period (in years) 5.28 years 5.79 years 5.52 years 5.75 years Dividend yield - % - % - % - % The Company used historical volatility to calculate the expected volatility as of June 30, 2015 and 2014 . Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company’s stock options. The expected holding period of stock options represents the period of time options are expected to be outstanding and is based on historical experience. The vesting period ranges from one to four years and the contractual life is ten years. Stock- based c ompensation expense related to stock options, restricted stock units and the ESPP for the three and six months ended June 30, 2015 and 2014 was allocated as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 (in thousands) Cost of revenues $ 15 $ 30 $ 36 $ 58 Sales and marketing 107 74 194 144 General and administrative 548 356 997 697 Research and development 22 12 45 20 Total stock-based compensation $ 692 $ 472 $ 1,272 $ 919 On April 28, 2015, the Company announced the appointment of James Green to its Board of Directors and the retirement of Robert Dishman from our Board of Directors . As part of Dr. Dishman’s retirement, the Company ( i ) awarded an unrestricted stock award to Dr. Dishman on April 28, 2015, having an aggregate cash value of $80,000, (ii) accelerated the vesting of all outstanding stock options and restricted stock units that were unvested as of April 28, 2015, and (iii) extended the post-retirement option exercise period for each option to the earlier to occur of the respective scheduled expiration date or April 28, 2016. Total compensation expense recognized as part of general and administrative expenses for the three and six months ended June 30, 2015 , as part of these modifications, was approximately $0.1 million. The Company did not capitalize any stock-based compensation. Earnings per share Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options and restricted stock units into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Basic 33,569,180 32,045,314 33,240,467 31,946,654 Effect of assumed conversion of employee and director stock options and restricted stock units 1,456,470 900,618 - 988,801 Diluted 35,025,650 32,945,932 33,240,467 32,935,455 Excluded from the shares used in calculating the diluted earnings per common share in the above table are options to purchase approximately 1,264,875 and 2,477,884 shares of common stock for the three months ended June 30, 2015 and 2014 , respectively, as the impact of these shares would be anti-dilutive. Excluded from the shares used in calculating the diluted earnings per common share in the above table are options to purchase approximately 5,169,376 and 2,578,743 shares of common stock for the six months ended June 30, 2015 and 2014 , respectively, as the impact of these shares would be anti-dilutive.

Long Term Debt

Long Term Debt	6 Months Ended
	Jun. 30, 2015
Long Term Debt Disclosure [Abstract]
Long Term Debt Disclosure [Text Block]	14. Long Term Debt On August 7, 2009, the Company entered into an Amended and Restated Revolving Credit Loan Agreement related to a $20.0 million revolving credit facility with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders (as amended, the “2009 Credit Agreement”) . On September 30, 2011, the Company entered into the First Amendment to the Amended and Restated Revolving Credit Loan Agreement (the “First Amendment”) with Bank of America as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The First Amendment extended the maturity date of the credit facility to August 7, 2013 and reduced the interest rate to the London Interbank Offered Rate plus 3.0%. On October 4, 2012, the Company entered into the Second Amendment to the Amen ded and Restated Revolving Credit Loan Agreement (the “Second Amendment”) with Bank of America as agent, and Bank of America and Brown Brothers Harriman & Co as lende rs. The Second Amendment extended the maturity date of the credit facility to August 7, 20 14 . On March 29, 2013, the Company entered into a Second Amended and Restated Revolving Credit Agreement ( as amended, the “Credit Agreement”) with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders , that amended and restated the 2009 Credit Agreement . The Credit Agreement converted the Company’s existing outstanding revolving advances into a term loan in the principal amount of $15.0 million (the “Term Loan”), provides a revolving credit facility in the maximum princ ipal amount of $25.0 million (“Revolving Line”) and provides a delayed draw term loan of up to $15.0 million (the “DDTL”) to fund capital contributions to the Company’s former subsidiary, HART. The maximum amount available under the Credit Agreement is $5 0.0 million as borrowings against the DDTL in excess of $10.0 million results in a dollar for dollar reduction in the Revolving Line capacity. The Revolving Line, Term Loan and DDTL each have a maturity date of March 29, 2018 (the maturity date of the Revo lving Line was extended from March 29, 2016 in connection with the Third Amendment discussed below ). On October 31, 2013, the Company amended the Credit Agreement to reduce the DDTL from up to $15.0 million to up to $10. 0 million and allow for an additional $5.0 million to be available for drawing as advances under the Revolving Line. On April 24, 2015, the Company entered into the Third Amendment to the Second Amended and Restated Credit Agreement (the “Third Amendment” ). The Third Amendment extended the maturity date of the Revolving Line to March 29, 2018 and reduced the interest rates on the Revolving Line, Term Loan and DDTL. B orrowings under the Term Loan and the DDTL accrued interest at a rate based on either the effective London Interbank Offered Rate (LIBOR) for certain interest periods selected by the Company, or a daily floating rate based on the British Bankers’ Association (BBA) LIBOR as published by Reuters (or other commercially available source providing q uotations of BBA LIBOR), plus in either case, a margin of 2.75 %. Additionally, t he Revolving Line accrued interest at a rate based on either the effective LIBOR for certain interest periods selected by the Company, or a daily floating rate based on the BBA LIBOR, plus in either case, a margin of 2. 25 %. The Company was required to fix the rate of interest on at least 50% of the Term Loan and the DDTL through the purchase of interest rate swaps. The Term Loan and DDTL each have interest payments due at the e nd of the applicable LIBOR period, or monthly with respect to BBA LIBOR borrowings, and principal payments due quarterly. The Revolving Line has interest payments due at the end of the applicable LIBOR period, or monthly with respect to BBA LIBOR borrowing s. On June 30, 2015, the Company entered into the Fourth Amendment to the Second Amended and Restated Credit Agreement (the “Fourth Amendment”), which amended the Company’s quarterly minimum fixed charge coverage financial covenant. The loans evidenced by the Credit Agreement, or the Loans, are guaranteed by all of the Company’s direct and indirect domestic subsidiaries, and secured by substantially all of the assets of the Company and the guarantors. The Loans are subject to res trictive covenants under the Credit Agreement, and financial covenants that require the Company and its subsidiaries to maintain certain financial ratios on a consolidated basis, including a maximum leverage, minimum fixed charge coverage and minimum worki ng capital. Prepayment of the Loans is allowed by the Credit Agreement at any time during the terms of the Loans. The Loans also contain limitations on the Company’s ability to incur additional indebtedness and requires lender approval for acquisitions fun ded with cash, promissory notes and/or other consideration in excess of $6.0 million and for acquisitions funded solely with equity in excess of $10.0 million. As of June 30, 2015 and December 31, 2014 , the C ompany had borrowings of $ 20.7 million and $ 21.5 million, respectively, outstanding under its Credit Agreement. As of June 30, 2015 , the Company was in compliance with all financial covenants contained in the Credit A greement, was subject to covenant and w orking capital borr owing restriction s and had available borrowing capacity under its Credit Agreement of $ 8.5 million. As of June 30, 2015 , the weighted effective interest rates on the Company’s Term Loan, DDTL and Revolving Line borrowings were 3.96% , 3.43% and 2.44% , respectively. As of June 30, 2015 and December 31, 2014 , the Company’s borrowings were comprised of: June 30, December 31, 2015 2014 (in thousands) Long-term debt: Term loan $ 8,250 $ 9,750 DDTL 6,500 7,500 Revolving line 5,900 4,200 Total debt 20,650 21,450 Less: current installments (5,000) (5,000) Long-term debt $ 15,650 $ 16,450

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	15 . Derivatives The Company uses interest -rate -related derivative instruments to manage its exposure related to changes in interest rates on its variable -rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments. By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the f ailure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative co ntract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transaction s with carefully selected major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest -rat e contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures th at may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company’s outstanding or forecasted debt obligations as well as the Company’s offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company’s future cash flows. The Company uses variable -rate London Interbank Offered Rate (LIBOR) debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is p rudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LI BOR. These swaps change the variable -rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged. In accordance with its Credit Agreement, the Company was required to fix the rate of interest on at least 50% of its Term Loan and the DDTL through the purchase of interest rate swaps. On June 5, 2013, the Company entered into an interest rate swap contract with an original notional amount of $15.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark inter est rate (LIBOR) associated with the Company’s Term Loan. On November 29, 2013, the Company entered into a second interest rate swap contract with an original notional amount of $5.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the DDTL. The notional amount of the Company’s derivative instruments as of June 30, 2015 was $11 .5 million . The Term Loan swap contract converted specific variable-ra te debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 0.96% plus a ba nk margin of 3.0% . The DDTL swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate a ssociated with the Term Loan at 0.93% plus a bank margin of 3.0% .The interest rate swap s were designated as cash flow hedge s in accordance with ASC 815, Derivatives and Hedging . The following table presents the notional amo unt and fair value of the Company ’ s derivative instrument s as of June 30, 2015 and December 31, 2014 . June 30, 2015 June 30, 2015 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swap Other liabilities-non current $ 11,500 $ (39) December 31, 2014 December 31, 2014 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swap Other liabilities-non current $ 13,500 $ (18) (a) See Note 16 for the fair value measurements related to these financial instruments. All of the Company’s derivative instruments are designated as hedging instruments. The Company has structured its interest rate swap agreements to be 100% effective and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associate d with variable -rate, long -term debt obligations are reported in accumulated other comprehensive income (“AOCI”). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings. The Company’s interest rate swap agreement was deemed to be fully effective in accordance with ASC 815, and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI. The followin g table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive income for the three and six months ended June 30, 2015 and 2014 : Derivatives in Hedging Relationships Amount of gain or (loss) recognized in OCI on derivative (effective portion) Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 (in thousands) Interest rate swaps $ (12) $ (56) $ (71) $ (80) The following table summarizes the reclassifications out of accumulated other comprehensive (loss) income for the three and six months ended June 30, 2015 and 2014 : Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Location of amount Three Months Ended Six Months Ended reclassified from June 30, June 30, AOCI into income 2015 2014 2015 2014 (effective portion) (in thousands) Interest rate swaps $ 24 $ 34 $ 50 $ 69 Interest expense As of June 30, 2015 , $ 0.1 million of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next twelve months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these derivatives’ losses to earnings include the repricing of variable -rate debt. There were no cash flow hedges discontinued during 2015 or 2014 .

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	16 . Fair Value Measurements Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabi lities. Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s own assumptions. The following table s present the fair value hierarchy for those liabilities measured at fair value on a recurring basis: Fair Value as of June 30, 2015 (In thousands) Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 39 $ - $ 39 Fair Value as of December 31, 2014 (In thousands) Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 18 $ - $ 18 The Company uses the market approach technique to value its financial liabilities. The Company’s financial liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreement s was based on LIBOR yield curves at the reporting date.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax [Abstract]
Income Taxes Disclosure [Text Block]	17. Income Tax Income tax was an approximately $ 0.8 million benefit and $ 0.2 million expense for the three months ended June 30, 2015 and 2014 , respectively. The increased tax benefit for the three months ended June 30, 2015 reflects the incremental benefit recorded for the six months ended June 30, 2015 associated with actual results for the six-month period, as described below. The effective income tax rate was 19.5% for the three months ended June 30, 2014 . Discrete items included in the tax benefit for the three months ended June 30, 2015 included incentive stock option exercises partially offset by acquisition costs, the net of which was not material. Tax expense for t he three months ended June 30, 2014 included a discrete item for the exercise of incentive stock options . Income tax was an approximately $ 1.1 million benefit and $ 0.5 million expense for the six months ended June 30, 2015 and 2014 , respectively. The effective income tax rate was 53.1% for the six months ended June 30, 2015 , compared with 23.9% for the same period in 2014 . The tax benefit for the six months ended June 30, 2015 was based on the actual results for the six-month period rather than an effective tax rate estimated for the entire year. The Company determined that using a year-to-date approach resulted in a better estimate of income tax expense based o n its revised 2015 forecast of pre-tax income, mix of income across several jurisdictions with different statutory tax rates as well as the impact of permanent differences on its revised forecast of pre-tax income . The difference between the Company’s effective tax rate year over ye ar was primarily attributable the use of a year-to-date approach at June 30, 2015, the impact of increased research and development tax incentives and incentive stock option exercises on lower pre-tax earnings in 2015 as well as the mix of earnings between its domestic and foreign businesses, partially offset by nondeductible acquisition costs incurred versus 2014.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	18. Subsequent Events On August 3, 2015, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of restricted stock units with performance based vesting conditions, to members of the Company’s management team under the Third A&R Plan. The vesting of these restricted stock units is cliff-based and linked to the achievement of a relative total shareholder return of the Company’s common stock from August 3, 20 15 to the earlier of ( i ) August 3, 2018 or (ii) upon a change of control (measured relative to the Russell 3000 index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is 19 6,782 shares; the maximum amount is 150% of the target number.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2 . Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in U.S. GAAP. Under this standard, revenue will be re cognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. At its July 2015 meeting, the FASB agreed to defer the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar year-end public entities. The Company is assessing the new standard and has not yet determined the impact to the consolida ted financial statements. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . The update requires debt issuance costs related to a recognized debt liabili ty to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability, instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rat e. The update requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previousl y issued. The Company is evaluating the impact of ASU 2015-03 on its consolidated financial statements and the possibility of early adoption by the Company. In July 2015, the FASB issued ASU 2015-11, Simplifying Measurement of Inventory . The update requir es measurement of most inventory “at the lower of cost and net realizable value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured under the last-in, first-out (LIFO) method or the retail inven tory method (RIM). ASU 2015-11 requires prospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company is evaluating the impact of ASU 2015-11 on its consolidated financial statements and the possibility of early adoption by the Company.

Accumulated Other Comprehensi25

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2015
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income [Table Text Block]	Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2014 $ (4,658) $ (18) $ (3,557) $ (8,233) Other comprehensive loss before reclassifications (2,737) (71) - (2,808) Amounts reclassified from AOCI - 50 - 50 Other comprehensive loss (2,737) (21) - (2,758) Balance at June 30, 2015 $ (7,395) $ (39) $ (3,557) $ (10,991)
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Location of amount Three Months Ended Six Months Ended reclassified from June 30, June 30, AOCI into income 2015 2014 2015 2014 (effective portion) (in thousands) Interest rate swaps $ 24 $ 34 $ 50 $ 69 Interest expense

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2015
Acquisition Disclosure [Abstract]
Schedule of Business Acquisitions [Table Text Block]	(in thousands) Tangible assets $ 4,165 Liabilities assumed (2,819) Net assets 1,346 Goodwill and intangible assets: Goodwill 2,061 Trade name 774 Customer relationships 1,627 Developed technology 1,338 Non-compete agreements 27 Deferred tax liabilities (1,245) Total goodwill and intangible assets, net of tax 4,582 Acquisition purchase price $ 5,928 Three Months Ended Six Months Ended June 30, 2014 June 30, 2014 (in thousands) Pro Forma Revenues $ 28,339 $ 55,612 Net income 1,096 1,889 (in thousands) Tangible assets $ 5,442 Liabilities assumed (1,207) Net assets 4,235 Goodwill and intangible assets: Goodwill 3,745 Trade name 1,008 Customer relationships 1,204 Developed technology 2,452 Non-compete agreements 148 Deferred tax liabilities (1,603) Total goodwill and intangible assets, net of tax 6,954 Acquisition purchase price $ 11,189 Three Months Ended Six Months Ended June 30, 2014 June 30, 2014 (in thousands) Pro Forma Revenues $ 28,780 $ 56,492 Net income 1,105 1,906 (in thousands) Tangible assets $ 1,278 Liabilities assumed (530) Net assets 748 Goodwill and intangible assets: Goodwill 946 Trade name 143 Customer relationships 308 Developed technology 363 Non-compete agreements 30 Deferred tax liabilities (325) Total goodwill and intangible assets, net of tax 1,465 Acquisition purchase price $ 2,213

Goodwill and Other Intangible27

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill And Other Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	Weighted Average June 30, 2015 December 31, 2014 Life (a) (in thousands) Amortizable intangible assets: Gross Accumulated Amortization Gross Accumulated Amortization Existing technology $ 16,399 $ (11,508) $ 15,538 $ (11,198) 7.6 Years Trade names 7,698 (2,826) 7,114 (2,557) 9.5 Years Distribution agreements/customer relationships 23,830 (11,238) 22,730 (10,681) 10.4 Years Patents 259 (76) 256 (49) 3.7 Years Total amortizable intangible assets 48,186 $ (25,648) 45,638 $ (24,485) Indefinite-lived intangible assets: Goodwill 41,081 39,822 Other indefinite-lived intangible assets 1,228 1,252 Total goodwill and other indefinite-lived intangible assets 42,309 41,074 Total intangible assets $ 90,495 $ 86,712 (a) Weighted average life as of June 30, 2015.
Goodwill Rollforward [Table Text Block]	(in thousands) Balance at December 31, 2014 $ 39,822 Goodwill arising from business combinations 2,061 Effect of change in currency translation (802) Balance at June 30, 2015 $ 41,081

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Inventories Disclosure [Abstract]
Schedule of Inventory [Table Text Block]	June 30, December 31, 2015 2014 (in thousands) Finished goods $ 10,607 $ 10,138 Work in process 1,256 946 Raw materials 11,205 9,447 Total $ 23,068 $ 20,531

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment Disclosure [Abstract]
Schedule Of Property Plant And Equipment [Table Text Block]	June 30, December 31, 2015 2014 (in thousands) Land, buildings and leasehold improvements $ 2,619 $ 2,595 Machinery and equipment 10,172 10,102 Computer equipment and software 7,300 6,322 Furniture and fixtures 1,324 1,125 Automobiles 54 56 21,469 20,200 Less: accumulated depreciation (15,705) (15,010) Property, plant and equipment, net $ 5,764 $ 5,190

Restructuring and Other Exit 30

Restructuring and Other Exit Costs (Tables)	6 Months Ended
	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring Plan Table [Table Text Block]	Severance Costs (in thousands) Restructuring charges $ 13 Cash payments - Restructuring balance at June 30, 2015 $ 13 Severance Costs (in thousands) Restructuring charges $ 88 Non-cash reversal of restructuring charges (6) Cash payments - Restructuring balance at June 30, 2015 $ 82 Severance Costs Other Total (in thousands) Restructuring balance at December 31, 2014 $ 626 $ - $ 626 Restructuring charges 39 35 74 Non-cash reversal of restructuring charges (58) - (58) Cash payments (129) (35) (164) Effect of change in currency translation 3 - 3 Restructuring balance at June 30, 2015 $ 481 $ - $ 481 Severance and Related Costs Other Total (in thousands) Restructuring balance at December 31, 2013 $ 1,434 $ - $ 1,434 Restructuring charges 195 175 370 Non-cash reversal of restructuring charges (115) - (115) Cash payments (1,184) (159) (1,343) Restructuring balance at June 30, 2014 $ 330 $ 16 $ 346 Severance and Related Costs (in thousands) Restructuring balance at December 31, 2013 $ 3 Non-cash reversal of restructuring charges (3) Restructuring balance at June 30, 2014 $ - Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 (in thousands) Restructuring charges $ 54 $ 115 $ 111 $ 252

Warranties (Tables)

Warranties (Tables)	6 Months Ended
	Jun. 30, 2015
Warranties Disclosure [Abstract]
Warranty Rollforward Disclosure [Table Text Block]	Beginning Additions/ Ending Balance Payments (Credits) Other Balance (in thousands) Year ended December 31, 2014 $ 305 (102) 49 - $ 252 Six months ended June 30, 2015 $ 252 (25) (73) 3 $ 157

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2015
Employee Benefit Plans Disclosure [Abstract]
Schedule of Changes in Projected Benefit Obligations [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 (in thousands) Components of net periodic benefit cost: Service cost $ - $ (8) $ - $ - Interest cost 190 227 367 448 Expected return on plan assets (179) (167) (345) (330) Net amortization loss 81 46 156 91 Net periodic benefit cost $ 92 $ 98 $ 178 $ 209

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2015
Leases Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Operating Leases (in thousands) 2016 $ 1,631 2017 1,539 2018 1,511 2019 1,315 2020 1,315 Thereafter 4,502 Net minimum lease payments $ 11,813

Capital Stock (Tables)

Capital Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Capital Stock Disclosure [Abstract]
Schedule Of Stock Options And Restricted Stock Units Activity Rollforward [Table Text Block]	Stock Options Restricted Stock Units Weighted Stock Average Restricted Options Exercise Stock Units Grant Date Outstanding Price Outstanding Fair Value Balance at December 31, 2014 6,263,112 $ 3.42 306,397 $ 4.30 Granted 863,000 5.51 254,685 5.56 Exercised (1,710,681) 3.04 - - Vested (RSUs) - - (237,188) - Cancelled / forfeited (246,055) 4.01 - - Balance at June 30, 2015 5,169,376 $ 3.87 323,894 $ 5.30
Table Of Assumptions [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Volatility 39.35 % 57.16 % 41.08 % 56.83 % Risk-free interest rate 1.70 % 1.80 % 1.72 % 1.78 % Expected holding period (in years) 5.28 years 5.79 years 5.52 years 5.75 years Dividend yield - % - % - % - %
Stock Based Compensation Expense Activity By Function [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 (in thousands) Cost of revenues $ 15 $ 30 $ 36 $ 58 Sales and marketing 107 74 194 144 General and administrative 548 356 997 697 Research and development 22 12 45 20 Total stock-based compensation $ 692 $ 472 $ 1,272 $ 919
Basic and Diluted Shares [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Basic 33,569,180 32,045,314 33,240,467 31,946,654 Effect of assumed conversion of employee and director stock options and restricted stock units 1,456,470 900,618 - 988,801 Diluted 35,025,650 32,945,932 33,240,467 32,935,455

Long Term Debt (Tables)

Long Term Debt (Tables)	6 Months Ended
	Jun. 30, 2015
Long Term Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	June 30, December 31, 2015 2014 (in thousands) Long-term debt: Term loan $ 8,250 $ 9,750 DDTL 6,500 7,500 Revolving line 5,900 4,200 Total debt 20,650 21,450 Less: current installments (5,000) (5,000) Long-term debt $ 15,650 $ 16,450

Derivative (Tables)

Derivative (Tables)	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	June 30, 2015 June 30, 2015 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swap Other liabilities-non current $ 11,500 $ (39) December 31, 2014 December 31, 2014 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swap Other liabilities-non current $ 13,500 $ (18) (a) See Note 16 for the fair value measurements related to these financial instruments.
Schedule of Cash Flow Hedges Included in AOCI [Table Text Block]	Derivatives in Hedging Relationships Amount of gain or (loss) recognized in OCI on derivative (effective portion) Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 (in thousands) Interest rate swaps $ (12) $ (56) $ (71) $ (80)
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Location of amount Three Months Ended Six Months Ended reclassified from June 30, June 30, AOCI into income 2015 2014 2015 2014 (effective portion) (in thousands) Interest rate swaps $ 24 $ 34 $ 50 $ 69 Interest expense

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis [Table Text Block]	Fair Value as of June 30, 2015 (In thousands) Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 39 $ - $ 39 Fair Value as of December 31, 2014 (In thousands) Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 18 $ - $ 18

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Income (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	$ (8,233)
Other Comprehensive Income (Loss) before Reclassifications	(2,808)
Reclassification from Accumulated Other Comprehensive Income	50
Other Comprehensive Income (Loss), Net of Tax, total	(2,758)
Closing Balance	(10,991)
Foreign currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(4,658)
Other Comprehensive Income (Loss) before Reclassifications	(2,737)
Reclassification from Accumulated Other Comprehensive Income	0
Other Comprehensive Income (Loss), Net of Tax, total	(2,737)
Closing Balance	(7,395)
Derivatives qualifying as hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(18)
Other Comprehensive Income (Loss) before Reclassifications	(71)
Reclassification from Accumulated Other Comprehensive Income	50
Other Comprehensive Income (Loss), Net of Tax, total	(21)
Closing Balance	(39)
Defined benefit pension plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(3,557)
Other Comprehensive Income (Loss) before Reclassifications	0
Reclassification from Accumulated Other Comprehensive Income	0
Other Comprehensive Income (Loss), Net of Tax, total	0
Closing Balance	$ (3,557)

Accumulated Other Comprehensi39

Accumulated Other Comprehensive Income (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Reclassifications Out of Accumulated Other Comprehensive Income [Line Items]
Derivatives Reclassification Adjustment from AOCI, net tax	$ (24)	$ (34)	$ (50)	$ (69)
Reclassification from Accumulated Other Comprehensive Income			$ (50)

Acquisitions (Narratives) (Deta

Acquisitions (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Business Acquisition Direct Acquisition Costs In Income Statement	$ 0.2	$ 0.2	$ 0.8	$ 0.2

Acquisitions (Details 1)

Acquisitions (Details 1) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jan. 08, 2015	Oct. 02, 2014
Multi Channel Systems MCS GmbH [Member]
Business Acquisition [Line Items]
Tangible Assets Acquired				$ 5,442
Liabilities Assumed				(1,207)
Net Tangible Assets Acquired				4,235
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Goodwill Amount				3,745
Deferred Tax Liabilities				1,603
Business Acquisition Purchase Price Allocation Total Intangible Assets Amount Including Goodwill				6,954
Total Acquisition Purchase Price				11,189
Business Acquisition, Cost of Acquired Entity 1 [Abstract]
Business Acquisition Cost Of Acquired Entity Purchase Price 1				11,189
Business Acquisitions Pro Forma Revenue	$ 28,780	$ 56,492
Business Acquisitions Pro Forma Net Income Loss	1,105	1,906
Multi Channel Systems MCS GmbH [Member] | Unpatented Technology [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				1,338
Multi Channel Systems MCS GmbH [Member] | Customer Relationships [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				1,627
Multi Channel Systems MCS GmbH [Member] | Trade Names [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				774
Multi Channel Systems MCS GmbH [Member] | Non compete Agreements [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				27
Triangle BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Tangible Assets Acquired				1,278
Liabilities Assumed				(530)
Net Tangible Assets Acquired				748
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Goodwill Amount				946
Deferred Tax Liabilities				325
Business Acquisition Purchase Price Allocation Total Intangible Assets Amount Including Goodwill				1,465
Total Acquisition Purchase Price				2,213
Business Acquisition, Cost of Acquired Entity 1 [Abstract]
Business Acquisition Cost Of Acquired Entity Purchase Price 1				2,213
Triangle BioSystems, Inc. [Member] | Customer Relationships [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				308
Triangle BioSystems, Inc. [Member] | Trade Names [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				143
Triangle BioSystems, Inc. [Member] | Patented Technology [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				363
Triangle BioSystems, Inc. [Member] | Non compete Agreements [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				$ 30
HEKA Elektronik [Member]
Business Acquisition [Line Items]
Tangible Assets Acquired			$ 4,165
Liabilities Assumed			2,819
Net Tangible Assets Acquired			1,346
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Goodwill Amount			2,061
Deferred Tax Liabilities			1,245
Business Acquisition Purchase Price Allocation Total Intangible Assets Amount Including Goodwill			4,582
Total Acquisition Purchase Price			5,928
Business Acquisition, Cost of Acquired Entity 1 [Abstract]
Business Acquisition Cost Of Acquired Entity Purchase Price 1			5,928
Business Acquisitions Pro Forma Revenue	28,339	55,612
Business Acquisitions Pro Forma Net Income Loss	$ 1,096	$ 1,889
HEKA Elektronik [Member] | Unpatented Technology [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets			1,338
HEKA Elektronik [Member] | Customer Relationships [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets			1,627
HEKA Elektronik [Member] | Trade Names [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets			774
HEKA Elektronik [Member] | Non compete Agreements [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets			$ 27

Goodwill and Other Intangible42

Goodwill and Other Intangible Assets (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Goodwill And Other Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 678	$ 587	$ 1,471	$ 1,221
Estimated Amortization Expense Next Twelve Months	2,800		2,800
Estimated Amortization Expense Year 2	2,800		2,800
Estimated Amortization Expense Year 3	2,500		2,500
Estimated Amortization Expense Year 4	2,400		2,400
Estimated Amortization Expense Year 5	$ 2,200		$ 2,200

Goodwill and Other Intangible43

Goodwill and Other Intangible Assets (Details 1) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 48,186	$ 45,638
Finite-Lived Intangible Assets, Accumulated Amortization	(25,648)	(24,485)
Goodwill	41,081	39,822
Other indefinite lived intangible assets	1,228	1,252
Total goodwill and other indefinite lived intangible assets	42,309	41,074
Total intangible assets	90,495	86,712
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	16,399	15,538
Finite-Lived Intangible Assets, Accumulated Amortization	$ (11,508)	(11,198)
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 7 months 6 days
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 7,698	7,114
Finite-Lived Intangible Assets, Accumulated Amortization	$ (2,826)	(2,557)
Finite-Lived Intangible Assets, Weighted Average Useful Life	9 years 6 months
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 23,830	22,730
Finite-Lived Intangible Assets, Accumulated Amortization	$ (11,238)	(10,681)
Finite-Lived Intangible Assets, Weighted Average Useful Life	10 years 4 months 24 days
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 259	256
Finite-Lived Intangible Assets, Accumulated Amortization	$ (76)	$ (49)
Finite-Lived Intangible Assets, Weighted Average Useful Life	3 years 8 months 12 days

Goodwill and Other Intangible44

Goodwill and Other Intangible Assets (Details 2) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 39,822
Acquired during the period	2,061
Foreign currency translation adjustments related to goodwill balance	(802)
Goodwill, Ending Balance	$ 41,081

Inventories (Details 1)

Inventories (Details 1) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventories Disclosure [Abstract]
Finished Goods	$ 10,607	$ 10,138
Work in Process	1,256	946
Raw Materials	11,205	9,447
Total Inventories, Net	$ 23,068	$ 20,531

Property, Plant and Equipment46

Property, Plant and Equipment (Details 1) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 21,469	$ 20,200
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(15,705)	(15,010)
Property, plant and equipment, net	5,764	5,190
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,619	2,595
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	10,172	10,102
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	7,300	6,322
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,324	1,125
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 54	$ 56

Restructuring and Other Exit 47

Restructuring and Other Exit Cots (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)	$ 54	$ 115	$ 111	$ 252
Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)				370
Restructuring number of positions eliminated, percent	13.00%		13.00%
Employee Severance [Member] | Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)				195
Other Costs [Member] | Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)				$ 175

Restructuring and Other Exit 48

Restructuring and Other Exit Costs (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)	$ 54	$ 115	$ 111	$ 252
Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance				1,434
Restructuring charges (credits)				370
Restructuring Reserve, Settled with Cash				(1,343)
Restructuring Reserve, Accrual Adjustment				(115)
Restructuring Reserve, Ending Balance	346		346
Restructuring Plan 2014 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			626
Restructuring charges (credits)			74
Restructuring Reserve, Settled with Cash			(164)
Restructuring Reserve, Ending Balance	481		481
Restructuring Reserve, Translation Adjustment			3
Employee Severance [Member] | Restructuring Plan 2012 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance				3
Restructuring Reserve, Accrual Adjustment				(3)
Restructuring Reserve, Ending Balance		$ 0		0
Employee Severance [Member] | Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance				1,434
Restructuring charges (credits)				195
Restructuring Reserve, Settled with Cash				(1,184)
Restructuring Reserve, Accrual Adjustment				(115)
Restructuring Reserve, Ending Balance	330		330
Employee Severance [Member] | Restructuring Plan 2014 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			626
Restructuring charges (credits)			39
Restructuring Reserve, Settled with Cash			(129)
Restructuring Reserve, Ending Balance	481		481
Restructuring Reserve, Translation Adjustment			3
Employee Severance [Member] | Restructuring Plan Q1 2015 [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)			88
Restructuring Reserve, Settled with Cash			0
Restructuring Reserve, Ending Balance	82		82
Other Costs [Member] | Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance				0
Restructuring charges (credits)				175
Restructuring Reserve, Settled with Cash				(159)
Restructuring Reserve, Accrual Adjustment				0
Other Costs [Member] | Restructuring Plan 2014 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance				$ 0
Restructuring charges (credits)			35
Restructuring Reserve, Settled with Cash			(35)
Restructuring Reserve, Ending Balance	$ 0		0
Restructuring Reserve, Translation Adjustment			$ 0

Related Party Transactions (Nar

Related Party Transactions (Narratives) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 600,000	$ 400,000	$ 1,200,000	$ 800,000
HART Sublease Rent	44,000	41,000	86,000	81,000
Transition Services Charged to HART		41,000		101,000
Distribution Revenues From Spinnee	101,000	$ 31,000	149,000	$ 109,000
Multi Channel Systems MCS GmbH [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	58,000		113,000
Triangle BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 11,000		$ 21,000

Warranties (Details 1)

Warranties (Details 1) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Product Warranty Disclosure [Abstract]
Warranty, Beginning Balance	$ 252	$ 305
Warranty payments	(25)	(102)
Warranty additions	(73)	49
Warranty Other	3	0
Warranty, Ending Balance	$ 157	$ 252

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Employee Benefit Plans Disclosure [Abstract]
Expected employer contribution in current remaining fiscal year			$ 400
Fair Value Impairment Of Pension Assets		$ 600
Defined Benefit Plan Payments In Current Fiscal Year	$ 200	200	400	$ 400
Defined Benefit Plans Liabilities Noncurrent	4,600		4,600		$ 4,400
Unrealized losses on pension benefit obligation, net of tax	$ 0	$ 484	$ 0	$ 484

Employee Benefit Plans (Details

Employee Benefit Plans (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Benefit Plans Disclosure [Abstract]
Service Cost	$ 0	$ (8)	$ 0	$ 0
Interest Cost	190	227	367	448
Expected Return on Plan Assets	(179)	(167)	(345)	(330)
Net Amortization Loss	81	46	156	91
Curtailment Gain	0	0	0	0
Net Periodic Benefit Cost, Total	92	98	178	209
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Interest Cost	190	227	367	448
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Defined Benefit Plan Payments In Current Fiscal Year	$ 200	$ 200	$ 400	$ 400

Leases (Narratives) (Details)

Leases (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Leases Disclosure [Abstract]
Estimated Rental Expenses Current Year			$ 2.2
Operating Leases, Rent Expense, Net	$ 0.6	$ 0.4	$ 1.2	$ 0.8

Leases (Details 1)

Leases (Details 1) $ in Thousands	Jun. 30, 2015USD ($)
Leases Disclosure [Abstract]
2,016	$ 1,631
2,017	1,539
2,018	1,511
2,019	1,315
2,020	1,315
Thereafter	4,502
Operating Leases, Total Future Minimum Payments Due	$ 11,813

Capital Stock (Narratives) (Det

Capital Stock (Narratives) (Details) - USD ($)	Apr. 28, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Apr. 03, 2015	Dec. 31, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date				85.00%
Employee Stock Purchase Plan Shares Authorized		750,000		750,000		750,000
Stock issued during the year, Shares, Employee Stock Purchase Plans		26,181	31,116			611,369
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							17,508,929
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan							2,500,000
Equity Instruments Other than Options, Grants in Period				254,685
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		1,264,875	2,477,884	5,169,376	2,578,743
Percentage Of Outstanding Common Stock		20.00%		20.00%		20.00%
Weighted Average Estimated Black Scholes Value Of Option Grants		$ 2.08	$ 2.2	$ 2.21	$ 2.19
Preferred Stock - Shares Authorized		5,000,000		5,000,000		5,000,000		5,000,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 80,000
Accelerated Share Based Compensation Expense	$ 100,000

Capital Stock (Details 1)

Capital Stock (Details 1) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Apr. 03, 2015	Dec. 31, 2014
Capital Stock Disclosure [Abstract]
Opening Balance Stock Options Outstanding			6,263,112
Begining Balance Weighted Average Exercise Price			$ 3.42
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan					2,500,000
Options, Grants in Period, Gross			863,000
Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 5.51
Options, Forfeitures and Expirations in Period			(246,055)
Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price			$ 4.01
Closing Balance Stock Options Outstanding	5,169,376		5,169,376
Closing Balance Weighted Average Exercise Price	$ 3.87		$ 3.87
Begining Balance Restricted Stock Units Outstanding			306,397
Equity Instruments Other than Options, Grants in Period			254,685
Equity Instruments Other than Options, Vested in Period			(237,188)
Closing Balance Restricted Stock Units Outstanding	323,894		323,894
Begining Balance Grant Date Fair Value Of Restricted Stock Units			$ 4.3
Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			5.56
Closing Balance Grant Date Fair Value Of Restricted Stock Units	$ 5.3		$ 5.3
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Fair Value Assumptions, Expected Volatility Rate	39.35%	57.16%	41.08%	56.83%
Fair Value Assumptions, Risk Free Interest Rate	1.70%	1.80%	1.72%	1.78%
Fair Value Assumptions, Expected Term	5 years 3 months 10 days	5 years 9 months 14 days	5 years 6 months 7 days	5 years 9 months
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Options, Exercises in Period, Weighted Average Exercise Price			$ 3.04
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value			$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period			0
Preferred Stock - Shares Authorized	5,000,000		5,000,000			5,000,000
Stock Issued During Period Gross Stock Options Exercised			1,710,681

Capital Stock (Details 2)

Capital Stock (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 692	$ 472	$ 1,272	$ 919
Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]
Basic	33,569,180	32,045,314	33,240,467	31,946,654
Weighted Average Number Diluted Shares Outstanding Adjustment	1,456,470	900,618	0	988,801
Diluted	35,025,650	32,945,932	33,240,467	32,935,455
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 15	$ 30	$ 36	$ 58
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	22	12	45	20
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	107	74	194	144
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 548	$ 356	$ 997	$ 697

Capital Stock (Details 3)

Capital Stock (Details 3) - shares	Jun. 30, 2015	Dec. 31, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	5,169,376	6,263,112

Long Term Debt (Narratives) (De

Long Term Debt (Narratives) (Details) - USD ($) $ in Thousands	Apr. 24, 2015	Oct. 31, 2013	Mar. 29, 2013	Aug. 07, 2009	Jun. 30, 2015	Dec. 31, 2014
Credit Agreement [Line Items]
Previous Approved Credit Facility				$ 20,000
Secured Debt					$ 20,650	$ 21,450
Line of Credit Facility, Maximum Borrowing Capacity			$ 50,000
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on					50.00%	50.00%
Line of Credit Facility, Remaining Borrowing Capacity					$ 8,500
Interest Rate In Excess Of LIBOR On Credit Facility				3.00%
DDTL Threshold For Dollar For Dollar Reduction In Revolving Line			10,000
Transfer Of Delayed Draw Down Term Loan Capacity To Revolver Capacity		$ 5,000
Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold					6,000
Lender Approval To Fund Acquisition With Equity In Excess Of Threshold					10,000
Revolving Credit Facility [Member]
Credit Agreement [Line Items]
Secured Debt			$ 25,000		$ 5,900	$ 4,200
Maturity Dates			Mar. 29, 2016
Basis Spread Over LIBOR	2.25%
Interest Rate As Of Reporting Date					2.44%
Term Loan [Member]
Credit Agreement [Line Items]
Secured Debt			$ 15,000		$ 8,250	9,750
Maturity Dates			Mar. 29, 2018
Basis Spread Over LIBOR	2.75%
Interest Rate As Of Reporting Date					3.96%
Delayed Drawdown Term Loan [Member]
Credit Agreement [Line Items]
Secured Debt			$ 15,000		$ 6,500	$ 7,500
Maturity Dates			Mar. 29, 2018
Basis Spread Over LIBOR	2.75%
Maximum Borrowings Available Under The Current Credit Agreement		$ 10,000
Interest Rate As Of Reporting Date					3.43%

Long Term Debt (Details 1)

Long Term Debt (Details 1) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Mar. 29, 2013
Debt Instrument [Line Items]
Secured Debt	$ 20,650	$ 21,450
Current portion, long-term debt	(5,000)	(5,000)
Long-term debt	15,650	16,450
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Secured Debt	5,900	4,200	$ 25,000
Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt	8,250	9,750	15,000
Delayed Drawdown Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt	$ 6,500	$ 7,500	$ 15,000

Derivative (Narratives) (Detail

Derivative (Narratives) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Nov. 30, 2013	Jun. 05, 2013
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on	50.00%	50.00%
Deferred losses on derivative instruments accumulated in AOCI expected to be reclassified to earnings	$ 0.1
Derivative Interest Rate Swap Effective Percentage	100.00%
Delayed Drawdown Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps			$ 5
LIBOR Fixed Rate	0.93%
Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps				$ 15
LIBOR Fixed Rate	0.96%

Derivative (Details 1)

Derivative (Details 1) - Other liabilities-non current [Member] - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Notional Amount of Interest Rate Derivatives	$ 11,500	$ 13,500
Derivative Liability, Fair Value, Net	$ (39)	$ (18)

Derivative (Details 2)

Derivative (Details 2) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion	$ (12)	$ (56)	$ (71)	$ (80)
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion	$ 24	$ 34	$ 50	$ 69

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 39	$ 18
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	39	18
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 0	$ 0

Income Tax (Narratives) (Detail

Income Tax (Narratives) (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax [Abstract]
Effective Income Tax Rate	19.50%	53.10%	23.90%

Subsequent Events (Narratives)

Subsequent Events (Narratives) (Details) - shares	Aug. 03, 2015	Jun. 30, 2015
Subsequent Event [Line Items]
Equity Instruments Other than Options, Grants in Period		254,685
Subsequent Event [Member] | Performance Shares [Member]
Subsequent Event [Line Items]
Equity Instruments Other than Options, Grants in Period	196,782
Maximum Performance Shares Award Granted Percent	150.00%